

Information for Patients:

Neurologic Adverse Reactions

The following may be symptoms of ICANS:

- Confusion
- Being less alert (decreased consciousness)
- Difficulty speaking or slurred speech
- Shaking (tremor)
- Feeling anxious
- Feeling dizzy
- Headache

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com

This material fulfils a condition of the lisocabtagene maraleucel marketing authorisation and has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA).

Date of preparation: Nov 2024
Approved by MHRA: Dec 2024
2009-GB-2400007

BREYANZI® ▼
(lisocabtagene maraleucel)

Patient Card

UK Version 1.0

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Have this card with you at all times. Show it to any doctor/healthcare provider who sees you, including in an emergency.

- Tell any healthcare provider who sees you that you are being treated with lisocabtagene maraleucel.
- For at least 4 weeks after receiving lisocabtagene maraleucel, you should plan to stay close to the location where you received treatment.

 Bristol Myers Squibb®

Date of preparation: Nov 2024
Approved by MHRA: Dec 2024
2009-GB-2400007

I have been treated with lisocabtagene maraleucel

Important Contact Information

My Name (PRINT): _____

Name of lisocabtagene maraleucel
Treating Physician (PRINT): _____

Office/Hospital Phone Number: _____

After-hours Phone Number: _____

Hospital Name: _____

Date of lisocabtagene maraleucel
Infusion (DD/MM/YYYY): _____

Lot Number (PRINT): _____

Information for the Healthcare Provider:

This patient has received lisocabtagene maraleucel chimeric antigen receptor (CAR)-positive T-cell therapy, a cluster of differentiation (CD) 19-directed genetically modified autologous cell-based product.

Following treatment with lisocabtagene maraleucel, cytokine release syndrome (CRS) and/or neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), may occur, which may be fatal or life threatening. CRS may involve any organ system.

Contact patient's lisocabtagene maraleucel treating physician immediately for further information.

Please see lisocabtagene maraleucel's Summary of Product Characteristics and Package Leaflet which can be found at www.medicines.org.uk/emc.

Information for Patients:

Lisocabtagene maraleucel may cause side effects that are severe or life-threatening. **Call your lisocabtagene maraleucel treating physician or go to the accident & emergency department immediately if any of the following symptoms appear:**

Cytokine Release Syndrome

- Fever
- Chills or shaking
- Feeling tired
- Fast or uneven heartbeat
- Feeling light-headed and short of breath
- Headache